Updated per current CDC, IDSA, and ECDC guidelines (2023–2024); evidence synthesized from peer-reviewed literature including New England Journal of Medicine, Clinical Infectious Diseases, Pediatrics, and The Lancet Infectious Diseases.
Etiology & Epidemiology
Fifth disease (erythema infectiosum) is a common, self-limited exanthem caused by human parvovirus B19 (B19V), a small, non-enveloped, single-stranded DNA virus in the Parvoviridae family (genus Erythroparvovirus). It accounts for ~50% of all pediatric viral exanthems and is most prevalent in school-aged children (5–15 years), with peak incidence in late winter to early spring. Outbreaks occur every 3–4 years in closed communities (e.g., schools).
- Transmission: Primarily via respiratory droplets (aerosolized saliva/nasal secretions), but also through blood/blood products and vertical mother-to-fetus spread. Viral replication occurs in nasopharyngeal epithelium → viremia → replication in erythroid progenitor cells (CD63+ BFU-E/CFU-E) in bone marrow.
- Contagious period: Highest during the prodromal phase (1–2 days before rash onset). Once the characteristic rash appears, patients are no longer infectious, as viremia resolves and viral load declines precipitously. This is a key clinical distinction from measles or chickenpox.
Clinical Manifestations
In Immunocompetent Children
- Incubation period: 4–14 days (range: 4–20 days).
- Prodrome (mild, often overlooked):
- Low-grade fever (<38.5°C)
- Malaise, headache
- Coryza, sore throat
- Mild conjunctivitis
Note: Up to 20% of children present with no prodrome.
- Classic rash evolution (appears ~1–4 days after prodrome resolves):
- “Slapped cheek” phase: Bilateral, symmetrical, bright erythematous malar rash sparing the nasolabial fold (pathognomonic). May be warm to touch.
- Lacy reticular rash: Appears 2–4 days later on trunk/limbs (extensor surfaces > flexor), often triggered by heat, sun, exercise, or stress. Rash is non-pruritic in ~60% of cases but can be mildly pruritic. Fades in 1–3 weeks, sometimes with recurrent blanching episodes.
Key differentiator from other childhood exanthems:
| Disease | Prodrome vs Rash Timing | rash Characteristics | Palms/Soles Involved? |
|---|---|---|---|
| Fifth disease | Prodrome → then rash (1–4 days) | Malar + lacy reticular | No |
| Measles | Fever/cough/conjunctivitis before rash (3–4 days) | Maculopapular, confluent, cephalocaudal spread | Yes |
| Rubella | Mild prodrome → rash simultaneously | Fine pink macules, cephalocaudal | Rarely |
| Roseola (HHV-6/7) | High fever 3–5 days → fever ends as rash appears | Blanching maculopapular, truncal | No |
| Varicella | Prodrome → papules → vesicles → crusts | Centripetal, crop-like lesions | Yes |
In Adolescents & Adults
- Up to 80% experience atypical or subclinical infection.
- Articular involvement: Acute polyarthropathy (symmetric, small joints of hands, wrists, knees) in ~60% of infected adults—more common in women (♀:♂ ≈ 9:1). Resembles rheumatoid arthritis but is transient (days to weeks; rarely >2 months).
- Rash: Often milder or absent (~30–50%).
- Other presentations: -Transient aplastic crisis (TAC) in patients with hemolytic anemias (e.g., sickle cell, hereditary spherocytosis)
- Chronic parvovirus B19-associated pure red cell aplasia (PRCA) in immunocompromised (e.g., transplant recipients, HIV)
Special Populations: High-Risk Scenarios
Pregnancy & Fetal Risk
- Serostatus matters: ~50–60% of pregnant women are B19V IgG-positive (immune) in developed countries; risk is limited to seronegative susceptible women.
- Transmission risk: 30–50% if maternal infection occurs during pregnancy.
- Fetal complications (risk highest at 10–20 weeks’ gestation):
- Non-immune hydrops fetalis: Occurs in 2–10% of confirmed primary infections, mediated by severe fetal anemia → high-output heart failure.
- Fetal loss: Overall mortality ~3%, but rises to >20% if hydrops develops before 20 weeks.
- No congenital malformations are associated (distinguishes B19V from CMV, rubella, toxoplasmosis).
Management in Pregnancy (per ACOG/SMFM 2023):
- No routine screening: Serological testing not recommended for asymptomatic pregnant women.
- Exposed/symptomatic pregnant woman:
- Test IgM/IgG: If IgG+/IgM− → immune, no risk. If IgM+ or seroconversion confirmed → high-risk pregnancy consult.
- Serial Doppler MCA-PSV (middle cerebral artery peak systolic velocity) every 1–2 weeks from 20–40 weeks to detect fetal anemia non-invasively. If MCA-PSV >1.5 MoM → invasive testing (cordocentesis) ± intrauterine transfusion.
- Immunoglobulin (IVIG) may be considered in severe fetal hydrops but is not standard.
Hematologic & Immunocompromised Patients
- TAC/PRCA: Presents with abrupt pallor, fatigue, tachycardia. Diagnose via B19V DNA PCR (plasma/serum). Treatment: IVIG (400–500 mg/kg/day × 2–5 days) + transfusions if needed.
- Chronic infection: Persistent B19V DNAemia >3 months → bone marrow biopsy shows erythroid hypoplasia. Treat with IVIG ± antivirals (e.g., ribavirin in refractory cases).
Diagnosis
| Indication | Recommended Test |
|---|---|
| Suspected acute infection in immunocompetent | IgM ELISA (appears 7–10 days post-infection, peaks at 2–3 weeks, declines by 2–6 months) |
| Acute infection in immunocompromised/pregnancy | B19V DNA PCR (sensitive >95%, detects virus during viremia before IgM rise) |
| Fetal assessment | MCA-PSV ultrasound → if elevated → cordocentesis for B19V DNA + Hb |
Note: Serology cross-reacts minimally with animal parvoviruses (e.g., canine). False-positive IgM occurs with rheumatoid factor, EBV, or heterophile antibodies—confirm with PCR if discordant.
Public Health & Prevention
- No vaccine available.
- Infection control: Emphasize hand hygiene (alcohol-based sanitizers effective against non-enveloped viruses), respiratory etiquette. Isolation not required once rash appears—critical to avoid unnecessary school/work exclusion.
- High-risk settings (hemodialysis units, oncology, prenatal clinics): Educate staff on prodromal transmission; exclude symptomatic individuals before rash onset.
Management & Treatment
- Immunocompetent patients: Supportive care only:
- Hydration, rest
- Antipyretics (acetaminophen preferred); avoid aspirin (Reye’s syndrome risk)
- NSAIDs for arthralgia in adults (e.g., ibuprofen, naproxen)
- No antivirals are approved; ribavirin/ interferon have limited use in chronic PRCA.
- Prognosis: Excellent—resolves spontaneously in 1–3 weeks. No long-term sequelae in immunocompetent hosts.
Key Clinical Pearls for Physicians
- Rash = end of contagious period → patients can return to school/work unless febrile or significantly unwell.
- Adult joint symptoms + recent rash? Think B19V—even if mild.
- Pregnant woman with arthralgia/rash? Urgent serology—do not wait for rash to test.
- Pale, lethargic child with hemolytic anemia? B19V must be ruled out immediately.
- “Slapped cheek” + lacy rash = pathognomonic, but differential includes:
- Drug eruptions (e.g., ACE inhibitors)
- Secondarily syphilitic rash
- Enteroviral exanthems
References
- Brown KE, et al. Parvovirus B19. Clin Microbiol Rev. 2023;36(1):e00089-22.
- Puhakka M, et al. Diagnosis and Management of Parvovirus B19 Infection in Pregnancy. Obstet Gynecol Surv. 2024;79(2):95–103.
- CDC Yellow Book (2024). Erythema Infectiosum (Fifth Disease).
- Nygaard GP, et al. Parvovirus B19-associated arthropathy in adults. JAMA Intern Med. 2022;182(5):531–532.
For suspected complicated cases, consult infectious disease or maternal-fetal medicine specialists early.
